BioDiscovery introduces new CGH analysis module

By Wai Lang Chu

- Last updated on GMT

Related tags Gene

BioDiscovery has released a new array module for its Imagene
software that provides an advanced array-based DNA copy number
analysis and visualisation tool for the drug discovery sector.

The ImaGene aCGH (array Comparative Genomic Hybridisation) module provides researchers with one button analysis, normalisation and visualisation of DNA gains and losses.

CGH is a molecular-cytogenetic method that is used in the analysis of copy number changes (gains /losses) in the DNA content of tumour cells.

The method is based on the hybridisation of fluorescently labelled tumour (frequently Fluorescein - FITC) and normal DNA (frequently Rhodamine or Texas Red) to normal human metaphase preparations.

Using epiflourescence microscopy and quantitative image analysis, regional differences in the fluorescence ratio of tumour vs. control DNA can be detected and used for identifying abnormal regions in the tumour cell genome.

CGH will detect only unbalanced chromosomes changes. Structural chromosome aberrations such as balanced reciprocal translocations and inversions cannot be detected.

BioDiscovery's aCGH features a unique statistical algorithm, which is based on the CBS (Circular Binary Segmentation) approach. BioDiscovery have made improvements to the algorithm improving processing speed.

While allowing end user customisation, the aCGH module's interface eliminates the need for knowledge of advanced scripting languages or statistical settings.

"The new aCGH Module for ImaGene 7.0 is the only tool that fully integrates the task of array image processing with statistical CGH analysis with a full suite of integrated interactive visualisation tools,"​ said Soheil Shams, President of BioDiscovery.

"This new module is a natural progression of our pioneering work in microarray image and data analysis. This new module has been developed and beta-tested at leading CGH labs to offer the best solution possible."

ImaGene 7.0 is fully compatible with the latest generation dual core processors, and with Apple's Universal Binary platform.

Related topics Preclinical Research

Related news

Show more

Follow us


View more